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indicating reproducibility. Internal consistency was good
(alpha: Time 1 = 0.87, Time 2 = 0.91). The HOIQ showed
evidence of discriminative validity, being able to distin-
guish between individuals who differed according to self-
reported severity of outbreak. CONCLUSIONS: The
HOIQ represents an effective method for determining the
impact of a herpes outbreak. The measure is scheduled to
be used on a daily basis during such outbreaks in a trial
designed to determine the effectiveness of a new treatment
for RGH.
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OBJECTIVES: Little is known about the health-related
quality of life (HRQL) in patients with primary antibody
deﬁciencies (PAD) and their need of lifelong im-
munoglobulin G (IgG) replacement therapy. Daly et al.
(1991) developed a questionnaire, the Life Quality Index
(LQI), consisting of one sale of 15 items related to IgG
treatment. The higher the score, the better the treatment-
speciﬁc HRQL. The construct validity has never been
shown, nor has the instrument been related to patient-
reported data. METHODS: Of 58 patients (17 children,
41 adults) with PAD were treated with weekly IgG infu-
sions (Beriglobin P, Aventis Behring, Marburg) for 10
months. Beside other instruments, the patients answered
the LQI and a single-item related to their change in health
status at baseline, 6- and 10-months. Construct validity
was evaluated using explorative factor analysis using the
Kaiser criterion and a varimax rotation. For the evalua-
tion of clinical validity an anchor-based approach was
applied, i.e. the patients’ self-assessments of their health-
status changes over time were related to LQI changes over
time. RESULTS: There was a noteworthy improvement
for 9 LQI items in adults and for 12 LQI items in chil-
dren from baseline to 10-months. Exploratory factor
analysis suggested a 3-factor solution that accounted for
52% of the total variance. For patients reporting an
improvement in their health status, all mean changes in
LQI scores were positive, and in 10 of 15 items changes
larger than 0.5 were observed. Thus, an improved 
self-perceived health led to improved LQI scores. CON-
CLUSION: The LQI is well suited to capture treatment-
speciﬁc aspects of HRQL in patients with PAD receiving
IgG. The items could be aggregated into three sub-scales.
The anchor-based approach indicates that the LQI may
serve as a valid instrument to assess the patients’ percep-
tions of their treatment.
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OBJECTIVE: To evaluate the different European health
care structures involved in the care of Parkinson’s disease
(PD) as well as the economic impact of PD in European
countries (EC). METHODS: Data are generated by desk
top research (contacting national medical societies, PD
specialists, institutes for statistics, third party payers, 
ministries, support groups and conducting structured
database search). Reviewed data are: national treatment
guidelines and treatment patterns, hospitalization, reha-
bilitation, disease management programs and availability
of support groups. Epidemiologic data were elaborated
by systematic literature review. RESULTS: 1) In France
and the Czech Republic patients are mainly treated by
neurologists, while in Sweden patients are preferably
under care of General Practitioners. 2) Treatment guide-
lines are not standardized in Europe. 3) PD rehabilitation
is differently organized in the EC, however, paucity of
data precludes a detailed statement. United Kingdom
(UK) PD society is developing a network of PD specialist
nurses to co-ordinate multidisciplinary care, while in
Germany and other EC no disease management programs
exist. Total annual costs for PD differ: UK $280 million
(Haycock, 1995), France $411 million (LePen, 1999),
Sweden $136 million (Hagell, 2002) and Germany $1.0
billion (Dodel, 1998). Direct medical costs account for
20–40% of total costs depending on the Health care
system, indirect costs account for approximately 22–50%
of total costs in the UK (McMahon, 2000), Sweden
(Hagell, 2002), and Germany (Spottke, 2002), respec-
tively. Average length of stay differs among the EC
(Germany 21.1d, UK 29.4d, France 19d and Italy 16.4
d). CONCLUSION: PD care seems to be managed dif-
ferently in the EC analyzed. Despite the importance of the
disease detailed data are not easily accessible. One of the
aims of EuroPa is to gather this information and optimize
therapy for PD on an European level. These data are
crucial for a cost effective and optimized therapy for PD
patients.
